|
|
|
|
|
||||||||||||
|
|
|
|
|
|
|
|
价值评估 |
盈利(现时/预测)
-6.07/-0.93
|
企业价值
3.80M
|
资产负债 |
每股账面净值
1.07
|
现金流量 |
现金流量率
--
|
损益表 |
收益
0
|
每股收益
0.05
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|

同行比较之报价最少15分钟延迟
业务概览
|
|||
Palisade Bio Inc is a clinical-stage biopharma company focused on identifying and developing therapeutics that protect the integrity of the intestinal barrier. Its portfolio consists of a PALI-2108 for the treatment of IBD, including UC and CD, and is researching PALI-1908. |